2 Reasons Why This FDA Decision Could Add Billions to Regeneron's Revenue

The U.S. Food and Drug Administration granted Regeneron Pharmaceuticals' (NASDAQ: REGN) antibody treatment for the coronavirus authorization late last year. Regeneron reported $262 million in sales of REGEN-COV in the first quarter. Regeneron shares have increased about 5% year to date.